Novo Nordisk Faces a Trio of Headwinds as CagriSema’s FDA Verdict Looms
Published on 07/24/2026 at 19:01 | Redaktion boerse-global.de
Novo Nordisk’s stock is caught in a tug-of-war between pipeline optimism and mounting external pressures. The Danish drugmaker closed Thursday at €42.27 in European trading, eking out a 0.43 percent gain on the day but nursing a 3.80 percent weekly decline. At €43.09 on Friday, the shares sit 6.77 percent above their 50-day moving average — a modest recovery from the March trough of €30.25, yet still roughly 31 percent below the all-time high of €60.95 set in July 2025.
The company is fighting on multiple fronts simultaneously. A high-stakes FDA decision on its experimental obesity therapy CagriSema hangs over the fourth quarter, while a newly unveiled US tariff timeline threatens to reshape the pharmaceutical landscape. Adding to the noise, Novo Nordisk has taken rival Eli Lilly to court over what it calls misleading advertising in the GLP-1 market.
The CagriSema Countdown
All eyes remain fixed on CagriSema, the combination of amylin and GLP-1 that Novo Nordisk submitted for US regulatory approval in December 2025. The FDA has yet to set a formal PDUFA date, but the company expects a ruling in the fourth quarter of 2026. The drug is not yet approved in either the US or the European Union.
The pivotal question is whether CagriSema can compete head-to-head with Eli Lilly’s tirzepatide. A major comparative diabetes study reached a key milestone on July 16, when Novo Nordisk reported the trial as completed. The core data are now locked and could be published soon. A smaller comparator study on delivery devices was quietly withdrawn — a portfolio pruning move rather than a verdict on efficacy, the company has indicated.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Investors have not forgotten the February 23 setback, when CagriSema delivered 23.0 percent weight loss in the REDEFINE-4 obesity trial versus 25.5 percent for tirzepatide, missing the non-inferiority endpoint. Novo Nordisk shares plunged more than 12 percent in Copenhagen that day, while Eli Lilly gained roughly 4 percent in US pre-market trading. Kepler Capital Markets subsequently downgraded the stock from “Buy” to “Hold,” citing diminished confidence in near-term pipeline catalysts.
The upcoming diabetes data will either reinforce the narrative of a broad, competitive franchise or repeat the pattern of disappointment. The stock currently trades 42.46 percent above its 52-week low, suggesting the market has already priced in a degree of recovery. Confirmation from the data could fuel further upside; a repeat of the obesity trial outcome could erase recent gains quickly.
Tariffs Enter the Picture
While the pipeline drama unfolds, a new regulatory headache has emerged from Washington. President Donald Trump has unveiled a phased tariff plan for imported generic drugs. No duties will apply for the first two years starting August 1, but a 100 percent tariff kicks in from August 2028, rising to 200 percent a year later. Trump framed the escalation as a penalty for manufacturers that fail to build US production capacity in time.
The generic-focused tariffs come on top of an earlier 100 percent levy on patented pharmaceutical products, announced April 2 under Section 232, which gave large manufacturers a 120-day grace period. Novo Nordisk has already hedged against that risk: it is among more than a dozen major drugmakers — including Eli Lilly and Pfizer — that struck pricing agreements with the Trump administration. In exchange for committing to lower US prices linked to cheaper overseas rates, these companies secured a three-year exemption from tariffs on patented drugs.
The broader sector felt the jitters. Sandoz, the generic drugmaker, lost as much as 4.2 percent in Zurich on the tariff news. Novo Nordisk has been repeatedly cited among the decliners in the pharmaceutical space this week.
Legal Offensive Against Lilly
Adding to the complexity, Novo Nordisk has filed a lawsuit against Eli Lilly in a New Jersey federal court, accusing its US rival of running misleading advertising campaigns for the obesity injection Zepbound and the diabetes drug Mounjaro. The complaint alleges that Lilly compares its highest approved doses to lower doses of Novo Nordisk’s Wegovy and Ozempic while omitting the existence of its own higher-strength formulations.
The legal move is intended as an offensive tactic to level the competitive playing field. The market, however, has interpreted it differently — as a sign of growing pressure in the GLP-1 space rather than a clear competitive victory. Citi maintained its neutral rating on Novo Nordisk’s B-shares, though it nudged the price target slightly higher, signaling only limited upside. Of the 24 analysts covering the stock, the majority still recommend a hold.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Buyback Program Rolls On
Despite the headwinds, Novo Nordisk has kept its capital return program running. Since February 4, 2026, the company has repurchased nearly 25 million B-shares at an average price of 274.58 Danish kroner, for a total transaction value of approximately 6.85 billion kroner. That brings its treasury holdings to 42.1 million B-shares, or 0.9 percent of share capital. The current tranche is part of a larger buyback program worth up to 15 billion kroner, which runs through February 2027.
The Road Ahead
The stock is currently trading near its 50- and 200-day moving averages around the €40 level, where it finds support as long as GLP-1 volume growth and the oral Wegovy tablet’s outperformance offset pricing pressures baked into the company’s revised full-year guidance. Novo Nordisk now expects currency-adjusted sales growth of between minus 4 and minus 12 percent, with quarterly fluctuations, a forecast that has already been revised upward once on stronger GLP-1 expectations.
Two catalysts will determine the next leg for the shares: the release of the diabetes comparator data and the FDA’s CagriSema decision, which the company still expects in the fourth quarter. With annualized volatility at 27.10 percent, the stock is primed for sharp moves in either direction. The next scheduled milestone is the quarterly earnings report in early August, which will offer the market its first comprehensive update on how Novo Nordisk is navigating this crowded intersection of pipeline risk, trade policy, and courtroom strategy.
Ad
Novo Nordisk Stock: New Analysis - 24 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
